Last reviewed · How we verify

Dihydroxydibutylether group

Pusan National University Yangsan Hospital · FDA-approved active Small molecule Quality 2/100

Dihydroxydibutylether group is a Small molecule drug developed by Pusan National University Yangsan Hospital. It is currently FDA-approved. Also known as: Galeo® group.

At a glance

Generic nameDihydroxydibutylether group
Also known asGaleo® group
SponsorPusan National University Yangsan Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dihydroxydibutylether group

What is Dihydroxydibutylether group?

Dihydroxydibutylether group is a Small molecule drug developed by Pusan National University Yangsan Hospital.

Who makes Dihydroxydibutylether group?

Dihydroxydibutylether group is developed and marketed by Pusan National University Yangsan Hospital (see full Pusan National University Yangsan Hospital pipeline at /company/pusan-national-university-yangsan-hospital).

Is Dihydroxydibutylether group also known as anything else?

Dihydroxydibutylether group is also known as Galeo® group.

What development phase is Dihydroxydibutylether group in?

Dihydroxydibutylether group is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing